

Research Paper

## Carbapenem and cefoxitin resistance of *Klebsiella pneumoniae* strains associated with porin OmpK36 loss and DHA-1 $\beta$ -lactamase production

Weifeng Shi<sup>1</sup>, Kun Li<sup>1</sup>, Yun Ji<sup>1</sup>, Qinbo Jiang<sup>1</sup>, Yuyue Wang<sup>1</sup>, Mei Shi<sup>1</sup>, Zuhuang Mi<sup>2</sup>

<sup>1</sup>Department of Clinical Laboratory, Third Affiliated Hospital of Suzhou University, Changzhou, P.R. China.

<sup>2</sup>Wuxi Clone Gen-Tech Institute, Wuxi, P.R. China.

Submitted: April 03, 2011; Approved: September 10, 2012.

---

### Abstract

Clinical isolates of carbapenem-resistant *Klebsiella pneumoniae* (*K. pneumoniae*) strains are being increased worldwide. Five pan-resistant *K. pneumoniae* strains have been isolated from respiratory and ICU wards in a Chinese hospital, and reveal strong resistance to all  $\beta$ -lactams, fluoroquinolones and aminoglycosides. Totally 27  $\beta$ -lactamase genes and 2 membrane pore protein (porin) genes in 5 *K. pneumoniae* strains were screened by polymerase chain reaction (PCR). The results indicated that all of 5 *K. pneumoniae* strains carried *bla*TEM-1 and *bla*DHA-1 genes, as well as base deletion and mutation of *OmpK35* or *OmpK36* genes. Compared with carbapenem-sensitive isolates by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), the resistant isolates markedly lacked the protein band of 34-40 kDa, which might be the outer membrane proteins of OmpK36 according to the electrophoresis mobility. In addition, the conjugation test was confirmed that *bla*DHA-1 mediated by plasmids could be transferred between resistant and sensitive strains. When reserpine (30  $\mu$ g/mL) and carbonyl cyanide *m*-chlorophenylhydrazone (CCCP) (50  $\mu$ g/mL) were added in imipenem and meropenem, the MICs had no change against *K. pneumoniae* strains. These results suggest that both DHA-1  $\beta$ -lactamase and loss or deficiency of porin OmpK36 may be the main reason for the cefoxitin and carbapenem resistance in *K. pneumoniae* strains in our hospital.

**Key words:** *Klebsiella pneumoniae*, AmpC  $\beta$ -Lactamase, Porin, molecular biology.

---

### Introduction

*K. pneumoniae* is one of the most common pathogens in clinical infections, such as pneumonia, urinary tract infections, sepsis, wound infections, meningitis and other diseases. Multidrug-resistant *K. pneumoniae* strains are becoming a severe problem worldwide, and it usually carries one or more extended-spectrum  $\beta$ -lactamases (ESBLs) that confers the resistance to expanded-spectrum cephalosporins (Lee *et al.*, 2007; Huang and Hsueh, 2008). In recent years, *K. pneumoniae* strains have been reported to be resistant to most  $\beta$ -lactams through mutation genes encoded in chromosome, acquisition of genes from mobile plasmids and integrons (Maltezou *et al.*, 2009; Munoz-Price and Quinn, 2009).

Carbapenem antibiotics are very effective in the treatment of severe bacterial infections caused by ESBL- and AmpC enzymes-producing *K. pneumoniae* strains so that they have been widely used in clinics. Due to carbapenemases, metallo- $\beta$ -lactamases and porin loss, carbapenem-resistant *K. pneumoniae* strains are increasing (Landman *et al.*, 2009; Pournaras *et al.*, 2010). Up to now, it has been reported that the outer membrane proteins of *K. pneumoniae* strains contain three known porins including OmpK35, OmpK36, and OmpK37 (Hernandez-Alles *et al.*, 1999; Kaczmarek *et al.*, 2006). Furthermore, porins OmpK35 and OmpK36 play critical roles in the penetration of antibiotics into the cells, and the loss of OmpK35 or OmpK36 can resist or reduce susceptibility to cephalosporins and carbapenems, particularly in strains containing

Ambler group A, B, C, or D  $\beta$ -lactamase (Doumith *et al.*, 2009; Goldfarb *et al.*, 2009; Kontopoulou *et al.*, 2010).

In 2010, we isolated 5 *K. pneumoniae* strains resistant to almost all antibiotics from clinical specimens. The minimal inhibitory concentrations (MICs) of piperacillin, piperacillin/tazobactam, amoxicillin/clavulanic acid, cefoperazone/sulbactam, ceftazidime, ceftazidime/avopivoxil and aztreonam against 5 *K. pneumoniae* strains were larger than 128  $\mu\text{g}/\text{mL}$ , and the MICs of imipenem and meropenem against 5 *K. pneumoniae* strains were larger than 32  $\mu\text{g}/\text{mL}$ . In addition, these *K. pneumoniae* strains also revealed the resistance to ciprofloxacin, levofloxacin, gentamicin and amikacin (MIC  $\geq$  64  $\mu\text{g}/\text{mL}$ ). The objective of this study was to investigate the cause of high-level carbapenem resistance in *K. pneumoniae* strains. Except for *bla*TEM-1 and *bla*DHA-1 genes, carbapenem-resistant genes were not observed in 5 *K. pneumoniae* strains; however, the base deletion or mutation of *OmpK35* and *OmpK36* genes could lead to the alterations of amino acid sequences, protein configuration and pore size of porins, thus impeding the access of antimicrobials. Therefore, high-level resistance to ceftazidime and carbapenem in 5 *K. pneumoniae* clinical isolates is due to the combinatorial action from the production of *bla*DHA-1 beta-lactamase and the insertional inactivation or loss of porin *OmpK36*.

## Methods

### Strains and antimicrobial susceptibility testing

In 2010, 5 carbapenem-resistant *K. pneumoniae* (*Kp01*, *Kp02*, *Kp03*, *Kp04* and *Kp05*) strains were isolated from sputum, urine and deep venous catheter specimens in a Chinese hospital. Among 5 patients, 1 case was from respiratory ward and 4 cases were from ICU ward. The MICs of piperacillin, piperacillin/sulbactam, amoxicillin/clavulanic acid, cefoperazone/sulbactam, ceftazidime, ceftazidime/avopivoxil, cefepime, aztreonam, imipenem, meropenem, ciprofloxacin, levofloxacin, gentamicin and amikacin were performed by E-test (Oxoid), and *E. coli* ATCC25922 was used as the control.

### Extraction of $\beta$ -lactamase and three-dimensional test

Briefly, a colony was inoculated into 5 mL of tryptic soy broth overnight and the culture was grown at 35 °C for 4 h. The cells were concentrated by centrifugation, and crude enzyme extract was prepared by repeated freeze-thawing cycle for five times. The surface of a Mueller-Hinton agar plate was inoculated with *E. coli* strains as described by the standard disk diffusion method. A 30  $\mu\text{g}$  ceftazidime disk (Oxoid) was placed on the inoculated agar. With a sterile scalpel blade, 4 slit beginning 5 mm from the edge of the disk was cut in the agar in outward radial direction. By using a pipette, 40  $\mu\text{L}$  of crude enzyme extract was dispensed into each slit, beginning near the disk and mov-

ing outward. Slit overflow was avoided. The inoculated media were incubated overnight at 35 °C. Enhanced growth of the surface organism at the point where the slit intersected the zone of inhibition was considered a positive three-dimensional testing result and was interpreted as the evidence in the presence of AmpC beta-lactamase or ESBL. *K. pneumoniae* ATCC700603 and *Enterobacter cloacae* (*E. cloacae*) 029 M were used as the control strains.

### Transconjugation experiments

In order to determine if the resistance was transferable, transconjugation experiments were performed. Five isolates were used as the donors and *EC600* (Rif<sup>r</sup>) was used as the recipient in transconjugation experiments. The organisms were inoculated into 5 mL of Luria-Bertani (LB) broth (Difco) and incubated at 35 °C for 20 h with shaking. Two organisms were mixed together at a proportion of 1 : 2, and then incubated overnight at 35 °C with shaking. After centrifugation for 5 min at 4,000 g, the precipitate was mixed with 1 mL of distilled water and inoculated onto MacConkey agar plates containing 600  $\mu\text{g}/\text{mL}$  rifampin and 0.25  $\mu\text{g}/\text{mL}$  ceftazidime. Transparent colonies were selected from the agar plates and inoculated into MacConkey agar again for activation. The drug-resistant profile and plasmid electrophoresis were further analyzed.

### DNA extraction

Strains were grown overnight on MacConkey agar plates at 37 °C, and growth from approximately one-quarter of a plate was resuspended in 180  $\mu\text{L}$  of distilled water. A total of 200  $\mu\text{L}$  of buffer solution (0.01 mM Tris-HCl, pH 7.8; 0.005 M EDTA; 0.5% sodium dodecyl sulfate) and 20  $\mu\text{L}$  of proteinase K (1 mg/mL) were added. The mixture was incubated at 55 °C for 2 h, and then 400  $\mu\text{L}$  of phenol-chloroform solution was added, mixed with gentle agitation, and centrifuged at 12,000 g for 5 min. The supernatant was collected and DNA was precipitated after the addition of 0.5 volume of 7.5 M ammonium acetate and 2 volumes of ethanol. DNA was washed with 70% ethanol, dried, and resuspended with 100  $\mu\text{L}$  of Tris-EDTA buffer.

### Analysis of $\beta$ -lactamase and porin genes

The oligonucleotide primers were designed on the basis of the nucleotide sequence in GenBank (Table 1). The 27  $\beta$ -lactamase and 2 porin genes were screened by PCR. The primer pairs were shown in Table 1. The assay was carried out in 20  $\mu\text{L}$  of reaction mixture containing 0.5  $\mu\text{M}$  each primer, 10 mM KCl, 2 mM MgCl<sub>2</sub>, 8 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 10 mM Tris-HCl (pH 9.0), 200  $\mu\text{M}$  dNTP and 1 U Taq DNA polymerase. All amplification reactions were performed with an initial denaturation at 93 °C for 3 min followed by 35 cycles of denaturation at 93 °C for 1 min, an-

**Table 1** - Primers used in this study.

Target genes	Primer sequence (3' → 5')	Size (bp)	GenBank accession no. of reference
Class A $\beta$ -lactamases			
TEM	P1: AGGAAGAGTATGATTCAACA P2: CTCGTCGTTTGGTATGGC	535 bp	X54604
SHV	P1: TGCGCAAGCTGCTGACCAGC P2: TTAGCGTTGCCAGTGCTCGA	305 bp	AY326946
CTX-M-1 group	P1: ATGGTTAAAAAATCACTGCGC P2: TCCCGACGGCTTTCCGCCTT	833 bp	GU125714
CTX-M-2 group	P1: ATGATGACTCAGAGCATTCCG P2: TCCCGACGGCTTTCCGCCTT	833 bp	AY750915
CTX-M-8 group	P1: ATGATGAGACATCGCGTTAAGCGG P2: TTAATAACCGTCGGTGACGATTTTCGCG	876 bp	AF189721
CTX-M-9 group	P1: CGGCCTGTATTTTCGCTGTTG P2: TCCCGACGGCTTTCCGCCTT	793 bp	AB205197
CTX-M-25 group	P1: ATGATGAGAAAAAGCGTAAGCGGGCG P2: TCCCGACGGCTTTCCGCCTT	876 bp	AY157676
PER	P1: AGTCAGCGGCTTAGATA P2: CGTATGAAAAGGACAATC	978 bp	AJ621265
GES	P1: ATGCGCTTCATTCACGCAC P2: CTATTTGTCCGTGCTCAGG	846 bp	AY219651
VEB	P1: GCGGTAATTTAACCAGA P2: GCCTATGAGCCAGTGT	961 bp	AY536743
CARB	P1: AAAGCAGATCTTGTGACCTATTC P2: TCAGCGCGACTGTGATGTATAAAC	588 bp	S46063
KPC	P1: ATGTCACTGTATCGCCGTCTA P2: TTAGTCCCGTTGACGCCCAA	882 bp	GU086225
LAP	P1: ATGAAAAAGATCCGCCTTATTATAA P2: TTACCAGTTCTTAATTACTGAATC	858 bp	EF026092
Class B $\beta$ -lactamases			
IMP	P1: CGGCCGCAGGAGAGGCTTT P2: AACCAGTTTGCCTTACCAT	587 bp	AJ223604
VIM	P1: ATTCCGGTCGGAGAGGTCCG P2: GAGCAAGTCTAGACCGCCCG	633 bp	AY509609
SPM	P1: CTGCTTGGATTCATGGGCGCG P2: CCTTTCCGCGACCTTGCTCG	784 bp	AY341249
NDM	P1: TCAGCGCAGCTTGTGCGCCA P2: ATGGAATTGCCCAATATTATGCA	813 bp	HQ738352
Class C $\beta$ -lactamases			
LEN	P1: ATGCGTTATATTCGCCTGTG P2: GGCGCTCAGATGCTGCGC	591 bp	AM850914
OKP	P1: AAGCGCTTCCCGGCGACGTG P2: TTAGCGTTGCCAGTGCTCGA	362 bp	AM051141
DHA	P1: AACTTTCACAGGTGTGCTGGGT P2: CCGTACGCATACTGGCTTTGC	405 bp	AY585202
ACT	P1: TCGGTAAAGCCGATGTTGCGG P2: CTTCCACTGCGGCTGCCAGTT	303 bp	EF508682

Table 1 (cont.)

Target genes	Primer sequence (3' → 5')	Size (bp)	GenBank accession no. of reference
MOX	P1: GCTGCTCAAGGAGCACAGGAT P2: CACATTGACATAGGTGTGGTG	520 bp	EU515248
ACC	P1: ACAGCCTCAGCAGCCGGTTA P2: TTCGCCGAATCATCCCTAG	345 bp	AJ133121
FOX	P1: AACATGGGGTATCAGGGAGAT P2: CAAAGCGCGTAACCGGATTGG	190 bp	AY034848
Class D β-lactamases			
OXA-1 group	P1: CTGTTGTTTGGGTTTCGCAAG P2: CTTGGCTTTTATGCTTGATG	440 bp	GQ438248
OXA-2 group	P1: CAGGCGCTGTTTCGTGATGAGTT P2: GCCTTCTATCCAGTAATCGCC	233 bp	FJ855130
OXA-10 group	P1: GTCTTTCAAGTACGGCATT P2: GATTTTCTTAGCGGCAACTTA	822 bp	AY509609
Porin			
ompK35	P1: ATGATGAAGCGCAATATTCTGGCAGTGG P2: TCGGCTTTGTCGCCATTGCCGTC	684 bp	GU945384
ompK36	P1: ATGAAAGTTAAAGTACTGTCCCTC P2: GCCGGTATCTCTACCGACGAC	1076 bp	HM000057

nealing at 55 °C for 1 min and extension at 72 °C for 1 min. The final extension was performed at 72 °C for 7 min. Aliquot (20 µL) of each sample was subjected to electrophoresis by 2% agarose gels. The amplicons were purified with PCR Cleanup kits (Roche Molecular Biochemicals) and sequenced on an ABI PRISM 377 analyzer (Applied Biosystems).

### Outer membrane protein analysis

*K. pneumoniae* was inoculated overnight in 5 mL of LB medium at 35 °C with shaking, the culture was added in 200 mL of LB liquid medium at 35 °C with shaking for 5 h. After centrifugation (4 °C) for 5 min at 4,000 g, the supernatant was discarded. The precipitate was washed three times with 50 mM (pH 7.0) phosphate buffer solution (PBS), and suspended in 10 mM Tris-HCl (pH 7.4). The ultrasonic fragmentation of bacteria was performed in ice bath conditions. In order to remove unbroken bacteria, centrifugation was performed at 4,000 g for 30 min, and then the supernatant was centrifuged at 25,000 g for another 30 min. The precipitation was resuspended with buffer, and phenylmethylsulfonyl was added. The outer membrane protein was denatured at 100 °C for 5 min before electrophoresis and then separated by SDS-PAGE with Mini-sub cell horizontal electrophoresis tank (Biorad Co.). The gel concentration was 12.0%, and stained with Coomassie brilliant blue R250 for 30 min.

### Inhibitory effects of reserpine and CCCP against efflux

Susceptibility test was carried out using agar dilution method. MIC changes were observed in the absence or presence of reserpine (J & K Chemical) and CCCP (Sigma) at concentrations of 30 µg/mL and 50 µg/mL, respectively. An inoculum of each isolate at the amount of  $5 \times 10^4$  cfu/mL was inoculated onto MH medium containing serial dilutions of imipenem and meropenem. A phenotype for positive efflux was detectable after at least 4-fold dilutions of MIC for imipenem or meropenem in the absence or presence of reserpine and CCCP.

## Results

### Antimicrobial susceptibility test

*In vitro* tests showed that the MICs of piperacillin, piperacillin/tazobactam, amoxicillin/clavulanic acid, cefoperazone/sulbactam, cefoxitin, cefotaxime and aztreonam against 5 *K. pneumoniae* strains were larger than 128 µg/mL, and the MICs of imipenem or meropenem against 5 *K. pneumoniae* strains were larger than 32 µg/mL. In addition, 5 *K. pneumoniae* strains also revealed strong resistance to ciprofloxacin, levofloxacin, gentamicin and amikacin (Table 2).

**Table 2** - MICs of  $\beta$ -lactams, fluoroquinolones and aminoglycosides against *K. pneumoniae* strains.

Antimicrobial agents	MIC ( $\mu\text{g/mL}$ )					
	<i>Kp01</i>	<i>Kp02</i>	<i>Kp03</i>	<i>Kp04</i>	<i>Kp05</i>	<i>EC600</i>
Piperacillin	> 256	> 256	> 256	> 256	> 256	1
Piperacillin/sulbactam	> 256	> 256	> 256	> 256	> 256	1
Amoxicillin/clavulanic acid	> 256	> 256	> 256	> 256	> 256	0.5
Ceftoxitin	> 256	> 256	> 256	> 256	> 256	4
Cefotaxime	> 256	> 256	> 256	> 256	> 256	0.25
Cefoperazone/sulbactam	> 256	> 256	> 256	> 256	> 256	$\leq 0.125$
Cefepime	128	128	> 256	> 256	128	$\leq 0.125$
Aztreonam	> 256	> 256	> 256	> 256	> 256	$\leq 0.125$
Imipenem	> 32	> 32	> 32	> 32	> 32	$\leq 0.125$
Meropenem	> 32	> 32	> 32	32	32	$\leq 0.125$
Ciprofloxacin	> 128	> 128	> 128	64	128	$\leq 0.125$
Levofloxacin	> 128	> 128	> 128	64	64	$\leq 0.125$
Gentamicin	> 128	> 128	> 128	> 128	128	$\leq 0.125$
Amikacin	> 128	> 128	> 128	128	128	$\leq 0.125$


*Kp01*, *Kp02*, *Kp03*, *Kp04* and *Kp05*: carbapenem-resistant *K. pneumoniae* strains.

### Three dimension test

All 5 isolates exhibited positive three-dimensional test results, and their extracts promoted the growth of one surface organism of *E. coli* ATCC25922 on MH agar. *E. cloacae* 029 M could produce AmpC enzyme to exhibit an interference with the growth of ATCC25922. ATCC700603 was used as the negative control (Figure 1).

### Sequence analysis of $\beta$ -lactamase, *OmpK35* and *OmpK36* genes

The PCR and sequence analysis showed that *Kp01*, *Kp02*, *Kp03*, *Kp04* and *Kp05* contained TEM and DHA  $\beta$ -lactamase genes. Compared with *bla*TEM-1 (Accession No. FJ668746) and *bla*DHA-1 (Accession No. HM193083) in GenBank, these strains shared 100% identity. Similarly, *OmpK35* and *OmpK36* genes in 5 multidrug-resistant *K. pneumoniae* strains were detected by PCR amplification and sequence analysis. Among 5 *K. pneumoniae* strains, the base deletions of *OmpK35* and *OmpK36* genes were observed in *Kp01* and *Kp03* strains, and the base deletion of *OmpK35* gene was also observed in *Kp02* and *Kp05*. In *OmpK36* gene, insertion and deletion as well as the mutations of short DNA fragment (1-5 bp) could result in the alteration of open reading frame and early termination of translation. In addition, mutations of *OmpK35* gene occurred in *Kp04* (Table 3). Compared with GU945384 in GenBank, *OmpK35* gene mutations of G  $\rightarrow$  C at base 465



**Figure 1** - Three-dimensional test for five strain isolates. (1A) Enhanced growth of *E. coli* ATCC25922 was observed near agar slits containing enzyme extracts of *Kp01*, *Kp02* and *E. cloacae* 029 M. Except for ATCC700603, all of them were AmpC producers. (1B) *Kp03*, *Kp04*, *Kp05* and *E. cloacae* 029 M could interfere with the growth of *E. coli* ATCC25922.

and T  $\rightarrow$  C at base 466 in *Kp04* could also result in the substitution from Gln to His at position 155 and substitution from Tyr to His at position 156. A new subtype has been registered in GenBank (Accession No. HQ259027).

### Transconjugation test of *K. pneumoniae*

*EC600* was used as the recipient in the conjugation studies. In addition, *bla*DHA-1 resistant genes from *Kp01*, *Kp02*, *Kp03* and *Kp05* were transferred into the recipient *EC600* and confirmed by PCR. *EC600* resulted in drug resistance from *Kp01*, *Kp02*, *Kp03* and *Kp05* to a certain degree, and the MICs of piperacillin, piperacillin/sulbactam,

amoxicillin/clavulanic acid and cefotaxime exhibited 2-16 fold increase (Table 4).

### SDS-PAGE of outer membrane protein

The outer membrane proteins of 4 strains were detected by SDS-PAGE. Compared with the sensitive strains, the lack of outer membrane proteins in 3 carbapenem-resistant *K. pneumoniae* strains (*Kp01*, *Kp02* and *Kp04*) were detected by SDS-PAGE, and molecular weights of these outer membrane proteins were 34-40 kDa, which suggested that only porin loss of OmpK36 in *Kp01*, *Kp02* and *Kp04* strains when compared with *K. pneumoniae* ATCC700603 and sensitive strains. In contrast, the porin of OmpK35 and OmpK36 was remained in *Kp03* (Figure 2).

### Inhibitory effects of reserpine and CCCP on the efflux of *K. pneumoniae*

All strains with a concentration of  $5 \times 10^4$  cfu/mL can grow in the presence of 256  $\mu\text{g/mL}$  reserpine and 128  $\mu\text{g/mL}$  CCCP. When reserpine (30  $\mu\text{g/mL}$ ) and CCCP (50  $\mu\text{g/mL}$ ) were added in imipenem and meropenem, no change of MICs was observed in the presence of reserpine and CCCP.


**Table 3** - Expression of two porins in five *K. pneumoniae* strains.

Strains	<i>bla</i> TEM-1	<i>bla</i> DHA-1	<i>OmpK36</i> gene	<i>OmpK35</i> gene
<i>Kp01</i>	+	+	Base deletion	Base deletion
<i>Kp02</i>	+	+	Insertion	Base deletion
<i>Kp03</i>	+	+	Base deletion	Base deletion
<i>Kp04</i>	+	+	Insertion	Mutation
<i>Kp05</i>	+	+	Insertion	Base deletion

**Table 4** - The antimicrobial susceptibility of transconjugants.

Antimicrobial agents	MIC ( $\mu\text{g/mL}$ )			
	Tr01	Tr02	Tr03	Tr05
Piperacillin	8	16	4	8
Piperacillin/sulbactam	4	8	8	4
Amoxicillin/clavulanic acid	4	8	4	4
Cefotaxime	0.5	1	0.5	1
Cefoperazone/sulbactam	0.25	0.125	0.125	0.25
Aztreonam	0.25	0.25	0.25	0.5
Cefepime	$\leq 0.125$	$\leq 0.125$	$\leq 0.125$	$\leq 0.125$
Imipenem	$\leq 0.125$	$\leq 0.125$	$\leq 0.125$	$\leq 0.125$
Meropenem	$\leq 0.125$	$\leq 0.125$	$\leq 0.125$	$\leq 0.125$
Ciprofloxacin	$\leq 0.125$	$\leq 0.125$	$\leq 0.125$	$\leq 0.125$
Amikacin	0.25	$\leq 0.125$	0.25	0.25

Transconjugants: Tr.



**Figure 2** - SDS-PAGE of outer membrane proteins. M: Marker; S1: ATCC700603; S2: sensitive strain.

### Discussion

In the present study, we screened 27  $\beta$ -lactamase genes including Ambler class A, B, C and D by using PCR technique. The metallo- $\beta$ -lactamases, OXA-type and KPC-type  $\beta$ -lactamases were not detected by PCR in 5 *K. pneumoniae* strains. However, all of 5 strains carried *bla*TEM-1 and *bla*DHA-1  $\beta$ -lactamase genes. DHA-1, a plasmid-mediated AmpC type  $\beta$ -lactamase belonging to Ambler class C, can confer the resistance to oxyiminocephalosporins (cefotaxime and ceftazidime) and cephamycins (cefotaxime and moxalactam), and transfer of the resistance has been confirmed by transconjugation (Lee, 2007; Ding *et al.*, 2008; Yamada *et al.*, 2009). In the present study, *bla*DHA-1 resistant genes from *Kp01*, *Kp02*, *Kp03* and *Kp05* may be transferred into the recipient *EC600*, leading to 2-16 fold MIC increase of piperacillin, piperacillin/sulbactam, amoxicillin/clavulanic acid and cefotaxime. These findings indicate that *bla*DHA-1  $\beta$ -lactamase gene can spread rapidly between the same and different bacteria.

The base deletion of *OmpK35* and *OmpK36* genes in *Kp01* and *Kp03* was simultaneously observed. Similarly, the base deletion of *OmpK35* also existed in *Kp02* and *Kp05*. In addition, there were still genetic insertion of *OmpK36* in *Kp02*, *Kp04* and *Kp05*. SDS-PAGE analysis of the OMPs revealed the only loss of *OmpK36* in *Kp01*, *Kp02* and *Kp04* strains when compared with *K. pneumoniae* ATCC700603 and a sensitive strains. However, the loss of porin was not observed in *Kp03*, which suggested that mutations or base deletions of porin-coding genes can lead to the alterations of open reading frame, amino acid sequences and protein configuration. Thus, the pore size of porin OmpK35 or OmpK36 can be affected and the accessibility

of drugs can be impeded. Moreover, the porin OmpK36 plays an important role in the resistance or reduced susceptibility to carbapenems in *K. pneumoniae* strains (Hernandez-Alles, 1999; Wang *et al.*, 2009). In this study, high-level carbapenem resistance in 5 *K. pneumoniae* strains was associated with the deletion or mutation of porin genes. The lack or deficiency of outer membrane protein can result in the change of permeability and reduction of cell accessibility for antibiotics or other drugs, which plays an important role in the main channels (Martinez-Martinez, 2008; Endimiani *et al.*, 2009; Jiang *et al.*, 2009; Landman, 2009). Therefore, blaDHA-1  $\beta$ -lactamases combined with the absence of outer membrane proteins may confer to the carbapenems and ceftazidime resistance in *K. pneumoniae* strains (Su *et al.*, 2008; Jiang *et al.*, 2010).

Efflux systems that contribute to antibiotic resistance have been described for a number of clinically important bacteria (Gugliera *et al.*, 2006; Coyne *et al.*, 2010; Husain and Nikaido, 2010). The overexpression of multi-drug efflux pumps can lead to low-level multi-drug resistance (Gugliera, 2006; Piddock, 2006). It has been reported that reserpine and CCCP were used as the pumps inhibitors (Shi *et al.*, 2005). Reserpine is a well-established inhibitor of efflux pumps among Gram-positive microorganisms and non-fermenting Gram-negative microorganisms. CCCP can destroy the proton gradient of bacterial transcytoplasm membrane, causing transport proteins to lose energy supply and eventually leading to the increasing accumulation of drug concentration (Zhang *et al.*, 2010). In this study, when reserpine and CCCP were added, MIC changes of imipenem and meropenem were not observed. The results indicated that the resistance of *K. pneumoniae* strains to carbapenems seems to be irrelevant to efflux.

Taken all together, the expression of porin OmpK36 coupled with blaDHA-1  $\beta$ -lactamase genes plays an important role in conferring resistance of *K. pneumoniae* strains to carbapenems and ceftazidime in our hospital. Our findings highlight the urgent need to develop the strategies for the prevention and control of infections. Limited application of antimicrobials, especially for fluoroquinolones and cephalosporins, may be the effective strategies.

## Acknowledgments

We really thank J Zhang and YH. Feng for their help of electrophoresis analysis.

## References

- Coyne S, Rosenfeld N, Lambert T, Courvalin P, Perichon B (2010) Overexpression of resistance-nodulation-cell division pump AdeFGH confers multidrug resistance in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 54:4389-4393.
- Ding H, Yang Y, Lu Q, Wang Y, Chen Y, Deng L, Wang A, Deng Q, Zhang H, Wang C (2008) The prevalence of plasmid-mediated AmpC  $\beta$ -lactamases among clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae* from five children's hospitals in China. *European journal of clinical microbiology & infectious diseases* 27:915-921.
- Doumith M, Ellington MJ, Livermore DM, Woodford N (2009) Molecular mechanisms disrupting porin expression in ertapenem-resistant *Klebsiella* and *Enterobacter* spp. clinical isolates from the UK. *J Antimicrob Chemother* 63:659-667.
- Endimiani A, DePasquale JM, Forero S, Perez F, Hujer AM, Roberts-Pollack D, Fiorella PD, Pickens N, Kitchel B, Casiano-Colón AE (2009) Emergence of blaKPC-containing *Klebsiella pneumoniae* in a long-term acute care hospital: a new challenge to our healthcare system. *Journal of Antimicrobial Chemotherapy* 64:1102.
- Goldfarb D, Harvey SB, Jessamine K, Jessamine P, Toye B, Desjardins M (2009) Detection of plasmid-mediated KPC-producing *Klebsiella pneumoniae* in Ottawa, Canada: evidence of intrahospital transmission. *J Clin Microbiol* 47:1920-1922.
- Gugliera P, Pasca MR, De Rossi E, Buroni S, Arrigo P, Manina G, Riccardi G (2006) Efflux pump genes of the resistance-nodulation-division family in *Burkholderia cenocepacia* genome. *BMC Microbiol* 6:66.
- Hernandez-Alles S, Alberti S, Alvarez D, Domenech-Sanchez A, Martinez-Martinez L, Gil J, Tomas JM, Benedi VJ (1999) Porin expression in clinical isolates of *Klebsiella pneumoniae*. *Microbiology* 145:673-679.
- Huang YT, Hsueh PR (2008) Antimicrobial drug resistance in Taiwan. *Int J Antimicrob Agents* 32 Suppl 3:174-178.
- Husain F, Nikaido H (2010) Substrate path in the AcrB multi-drug efflux pump of *Escherichia coli*. *Mol Microbiol* 78:320-330.
- Jiang X, Espedido BA, Partridge SR, Thomas LC, Wang F, Iredell JR (2009) Paradoxical effect of *Klebsiella pneumoniae* OmpK36 porin deficiency. *Pathology* 41:388-392.
- Jiang Y, Yu D, Wei Z, Shen P, Zhou Z, Yu Y (2010) Complete nucleotide sequence of *Klebsiella pneumoniae* multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA. *Antimicrob Agents Chemother* 54:3967-3969.
- Kaczmarek FM, Dib-Hajj F, Shang W, Gootz TD (2006) High-level carbapenem resistance in a *Klebsiella pneumoniae* clinical isolate is due to the combination of bla(ACT-1) beta-lactamase production, porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin PhoE. *Antimicrob Agents Chemother* 50:3396-3406.
- Kontopoulou K, Protonotariou E, Vasilakos K, Kriti M, Koteli A, Antoniadou E, Sofianou D (2010) Hospital outbreak caused by *Klebsiella pneumoniae* producing KPC-2 beta-lactamase resistant to colistin. *J Hosp Infect* 76:70-73.
- Landman D, Bratu S, Quale J (2009) Contribution of OmpK36 to carbapenem susceptibility in KPC-producing *Klebsiella pneumoniae*. *J Med Microbiol* 58:1303-1308.
- Lee K, Yong D, Choi YS, Yum JH, Kim JM, Woodford N, Livermore DM, Chong Y (2007) Reduced imipenem susceptibility in *Klebsiella pneumoniae* clinical isolates with plasmid-mediated CMY-2 and DHA-1 beta-lactamases co-mediated by porin loss. *Int J Antimicrob Agents* 29:201-206.
- Maltezou HC, Giakkoupi P, Maragos A, Bolikas M, Raftopoulos V, Papahatzaki H, Vrouhos G, Liakou V, Vatopoulos AC

- (2009) Outbreak of infections due to KPC-2-producing *Klebsiella pneumoniae* in a hospital in Crete (Greece). *J Infect* 58:213-219.
- Martinez-Martinez L (2008) Extended-spectrum beta-lactamases and the permeability barrier. *Clin Microbiol Infect* 14 Suppl 1:82-89.
- Munoz-Price LS and Quinn JP (2009) The spread of *Klebsiella pneumoniae* carbapenemases: a tale of strains, plasmids, and transposons. *Clin Infect Dis* 49:1739-1741.
- Piddock LJ (2006) Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. *Clin Microbiol Rev* 19:382-402.
- Pournaras S, Kristo I, Vrioni G, Ikonomidis A, Poulou A, Petropoulou D and Tsakris A (2010) Characteristics of meropenem heteroresistance in *Klebsiella pneumoniae* carbapenemase (KPC)-producing clinical isolates of *K. pneumoniae*. *J Clin Microbiol* 48:2601-2604.
- Shi WF, Jiang JP, Xu N, Huang ZM and Wang YY (2005) Inhibitory effects of reserpine and carbonyl cyanide *m*-chlorophenylhydrazone on fluoroquinolone resistance of *Acinetobacter baumannii*. *Chin Med J* 118:340-343.
- Su LH, Chu C, Cloeckert A and Chiu CH (2008) An epidemic of plasmids? Dissemination of extended spectrum cephalosporinases among *Salmonella* and other Enterobacteriaceae. *FEMS Immunology & Medical Microbiology* 52:155-168.
- Wang XD, Cai JC, Zhou HW, Zhang R and Chen GX (2009) Reduced susceptibility to carbapenems in *Klebsiella pneumoniae* clinical isolates associated with plasmid-mediated beta-lactamase production and OmpK36 porin deficiency. *J Med Microbiol* 58:1196-1202.
- Yamada Y, Ishii Y, Kouyama Y, Katho M, Odashiro R, Yamahata K, Tateda K, Yamaguchi K and Suwabe A (2009) Characterization of *Klebsiella pneumoniae* producing SHV-12 and DHA-1 beta-lactamases accompanied by carbapenem resistance during hospitalization in a chronic care ward in Japan. *J Chemother* 21:445-447.
- Zhang Y, Bao Q, Gagnon LA, Huletsky A, Oliver A, Jin S and Langae T (2010) ampG gene of *Pseudomonas aeruginosa* and its role in beta-lactamase expression. *Antimicrob Agents Chemother* 54:4772-4779.

All the content of the journal, except where otherwise noted, is licensed under a Creative Commons License CC BY-NC.